Effect of the Dysbindin Gene on Antimanic Agents in Patients with Bipolar I Disorder
Psychiatry Investigation
;
: 102-105, 2008.
Article
in English
| WPRIM
| ID: wpr-33386
ABSTRACT
OBJECTIVE:
We previously reported an association between dysbindin gene (DTNBP1) variants and bipolar I disorder (BID). This paper expands upon previous findings suggesting that DTNBP1 variants may play a role in the response to acute mood stabilizer treatment.METHODS:
A total of 45 BID patients were treated with antimanic agents (lithium, valproate, or carbamazepine) for an average of 36.52 (+/-19.87) days. After treatment, the patients were evaluated using the Clinical Global Impression (CGI) scale and the Young Mania Rating Scale (YMRS) and genotyped for their DTNBP1 variants (rs3213207 A/G, rs1011313 C/T, rs2005976 G/A, rs760761 C/T and rs2619522 A/C).RESULTS:
There was no association between the variants investigated and response to mood stabilizer treatment, even after considering possible stratification factors.CONCLUSION:
Although the small number of subjects is an important limitation in our study, DTNBP1 does not seem to be involved in acute antimanic efficacy.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Pharmacogenetics
/
Bipolar Disorder
/
Valproic Acid
/
Antimanic Agents
Limits:
Humans
Language:
English
Journal:
Psychiatry Investigation
Year:
2008
Type:
Article
Similar
MEDLINE
...
LILACS
LIS